Bayer proposes $7.2 billion settlement to resolve Roundup weedkiller cases - CBS News
Bayer proposes $7.2 billion settlement to resolve Roundup weedkiller cases CBS News
Hodgkin Lymphoma News
'My 7-year-old is adjusting to life after chemo' - BBC
'My 7-year-old is adjusting to life after chemo' BBC
Bayer Agrees to Pay $7.25 Billion to Settle Roundup Lawsuits - The New York Times
Bayer Agrees to Pay $7.25 Billion to Settle Roundup Lawsuits The New York Times
Non-Hodgkin Lymphoma | Puzolcabtagene Autoleucel: Pediatric First Approval - springermedicine.com
Non-Hodgkin Lymphoma | Puzolcabtagene Autoleucel: Pediatric First Approval springermedicine.com
SWOG S1826 3-year follow-up: N-AVD vs BV-AVD in adolescents with AS cHL - Lymphoma Hub
SWOG S1826 3-year follow-up: N-AVD vs BV-AVD in adolescents with AS cHL Lymphoma Hub
Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphoma - Nature
Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphoma Nature
Non-Hodgkin lymphoma survivor thankful for clinical trial - MD Anderson Cancer Center
Non-Hodgkin lymphoma survivor thankful for clinical trial MD Anderson Cancer Center
Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era - CancerNetwork
Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era CancerNetwork
Breast Cancer Risk After Chest Radiotherapy in Hodgkin Lymphoma Survivors: A Comprehensive Overview - ScienceDirect.com
Breast Cancer Risk After Chest Radiotherapy in Hodgkin Lymphoma Survivors: A Comprehensive Overview ScienceDirect.com
Hodgkin lymphoma (Hodgkin disease) - Mayo Clinic
Hodgkin lymphoma (Hodgkin disease) Mayo Clinic
First-Line Options in Advanced-Stage Classical Hodgkin Lymphoma: Weighing Efficacy, Toxicity, and Quality of Life in Decision-Making - ASCO Daily News
First-Line Options in Advanced-Stage Classical Hodgkin Lymphoma: Weighing Efficacy, Toxicity, and Quality of Life in Decision-Making ASCO Daily News
An Individualized Prediction Model for Early-Stage Classic Hodgkin’s Lymphoma - NEJM Evidence
An Individualized Prediction Model for Early-Stage Classic Hodgkin’s Lymphoma NEJM Evidence
Learn About How Survival Rates Are Improving With Hodgkin Disease - Verywell Health
Learn About How Survival Rates Are Improving With Hodgkin Disease Verywell Health
Classic Hodgkin’s Lymphoma With Epstein–Barr Viremia and Lymphadenopathy - Wiley Online Library
Classic Hodgkin’s Lymphoma With Epstein–Barr Viremia and Lymphadenopathy Wiley Online Library
Bayer offers $7.25bn to settle weedkiller cancer claims - BBC
Bayer offers $7.25bn to settle weedkiller cancer claims BBC
Impact of early failure of induction on transplant outcomes in Hodgkin lymphoma - Nature
Impact of early failure of induction on transplant outcomes in Hodgkin lymphoma Nature
Stage IV non-Hodgkin lymphoma survivor: Why I’m excited about MD Anderson coming to Austin - MD Anderson Cancer Center
Stage IV non-Hodgkin lymphoma survivor: Why I’m excited about MD Anderson coming to Austin MD Anderson Cancer Center
New treatment combination offers excellent results for early-stage Hodgkin lymphoma with less chemotherapy - MD Anderson Cancer Center
New treatment combination offers excellent results for early-stage Hodgkin lymphoma with less chemotherapy MD Anderson Cancer Center
Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials | Blood Cancer Journal - Nature
Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials | Blood Cancer Journal Nature
Clinical features and outcomes of newly diagnosed classical Hodgkin lymphoma patients in Saudi Arabia: a multicenter cohort study | Scientific Reports - Nature
Clinical features and outcomes of newly diagnosed classical Hodgkin lymphoma patients in Saudi Arabia: a multicenter cohort study | Scientific Reports Nature
An Individualized Prediction Model for Early-Stage Classic Hodgkin’s Lymphoma - NEJM Evidence
An Individualized Prediction Model for Early-Stage Classic Hodgkin’s Lymphoma NEJM Evidence
Nivolumab Plus AVD Reduces Disease Progression Risk in Adolescents With Advanced Classical Hodgkin Lymphoma - The ASCO Post
Nivolumab Plus AVD Reduces Disease Progression Risk in Adolescents With Advanced Classical Hodgkin Lymphoma The ASCO Post
Genome-scale spatial mapping of the Hodgkin lymphoma microenvironment identifies tumor cell survival factors - Nature
Genome-scale spatial mapping of the Hodgkin lymphoma microenvironment identifies tumor cell survival factors Nature
Sintilimab combined with AVD for the treatment of composite Hodgkin lymphoma and follicular lymphoma: a case report and literature review - Frontiers
Sintilimab combined with AVD for the treatment of composite Hodgkin lymphoma and follicular lymphoma: a case report and literature review Frontiers
Population based analysis of twenty year incidence trends of pediatric Hodgkin lymphoma in the United States - Nature
Population based analysis of twenty year incidence trends of pediatric Hodgkin lymphoma in the United States Nature
Subgroup analysis of treatment pathways and clinical outcomes in Hodgkin lymphoma in Latin America from the retrospective B-HOLISTIC study - Nature
Subgroup analysis of treatment pathways and clinical outcomes in Hodgkin lymphoma in Latin America from the retrospective B-HOLISTIC study Nature
New Model Predicts Risk of Progression in Early-Stage Classical Hodgkin Lymphoma - The ASCO Post
New Model Predicts Risk of Progression in Early-Stage Classical Hodgkin Lymphoma The ASCO Post
ASH 2025 | Congress coverage: Hodgkin lymphoma and T-cell lymphoma - Lymphoma Hub
ASH 2025 | Congress coverage: Hodgkin lymphoma and T-cell lymphoma Lymphoma Hub
Procalcitonin as a Potential Prognostic Marker in Advanced Hodgkin Lymphoma: A Case-Based Perspective - Cureus
Procalcitonin as a Potential Prognostic Marker in Advanced Hodgkin Lymphoma: A Case-Based Perspective Cureus
Contemporary epidemiological landscape of pediatric non-Hodgkin lymphoma: a global burden of disease analysis - Frontiers
Contemporary epidemiological landscape of pediatric non-Hodgkin lymphoma: a global burden of disease analysis Frontiers
Groundbreaking treatment fighting back against Non-Hodgkin’s Lymphoma - KPLC 7 News
Groundbreaking treatment fighting back against Non-Hodgkin’s Lymphoma KPLC 7 News
Case Report: Vanishing bile duct syndrome in Hodgkin’s lymphoma: a case highlighting jaundice and lymphadenopathy as early clues - Frontiers
Case Report: Vanishing bile duct syndrome in Hodgkin’s lymphoma: a case highlighting jaundice and lymphadenopathy as early clues Frontiers
EHA 2025 | Hodgkin lymphoma and T-cell lymphoma - Lymphoma Hub
EHA 2025 | Hodgkin lymphoma and T-cell lymphoma Lymphoma Hub
This Type of Rare Cancer May Be Missed in Young Adults—Here Are the Signs - Prevention
This Type of Rare Cancer May Be Missed in Young Adults—Here Are the Signs Prevention
An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma - Nature
An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma Nature
Follicular Lymphoma, Non-Hodgkin B-Cell Lymphoma - Moffitt
Follicular Lymphoma, Non-Hodgkin B-Cell Lymphoma Moffitt
Optimizing therapy for relapsed/refractory classic Hodgkin lymphoma in the era of PD-1 blockade - Wiley Online Library
Optimizing therapy for relapsed/refractory classic Hodgkin lymphoma in the era of PD-1 blockade Wiley Online Library
Outcomes of patients with Hodgkin lymphoma receiving Brentuximab Vedotin (BV) as maintenance therapy after ASCT according to previous exposure to BV. A retrospective analysis of the EBMT Lymphoma Working Party in collaboration with GELTAMO, FIL, - Nature
Outcomes of patients with Hodgkin lymphoma receiving Brentuximab Vedotin (BV) as maintenance therapy after ASCT according to previous exposure to BV. A retrospective analysis of the EBMT Lymphoma Working Party in collaboration with GELTAMO, FIL, Nature
Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers - Nature
Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers Nature
Years of Research Help Forge a New Path in Hodgkin Lymphoma Treatment - Dana-Farber Cancer Institute
Years of Research Help Forge a New Path in Hodgkin Lymphoma Treatment Dana-Farber Cancer Institute